Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Jul 2019

At a glance

  • Drugs Belimumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions
  • Acronyms BASE
  • Sponsors Human Genome Sciences
  • Most Recent Events

    • 25 Jun 2019 Planned End Date changed from 21 Jul 2022 to 22 Jul 2022.
    • 15 Jun 2019 Results (n=4003) presented at the 20th Annual Congress of the European League Against Rheumatism
    • 26 Apr 2018 Planned End Date changed from 20 Jul 2022 to 21 Jul 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top